Zebinix (PSYCHOANALEPTICS)

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zebinix (PSYCHOANALEPTICS)

Property Description
Active ingredient Escitalopram (S-enantiomer)
Form Tablet, Oral solution
Pharmacological class Psychoanaleptic, SSRI
Common use Mood stabilization, anxiety relief
Origin Synthetic, Enantiopure

Escitalopram is a synthetic drug classified as a psychoanaleptic—a type of medication intended to support mental function and mood. More specifically, this active ingredient is a Selective Serotonin Reuptake Inhibitor (SSRI). This classification confirms the drug's role in influencing brain chemistry related to emotional well-being.

Escitalopram is chemically distinct as an enantiopure drug; it is composed solely of the pharmacologically active S-enantiomer of its predecessor, racemic citalopram. This characteristic is a key differentiating factor, as the purification is intended to offer a cleaner pharmacological profile, focusing the substance's therapeutic action.


Composition, Origin, and Available Forms

The medication is a single-active-ingredient product, containing only the compound Escitalopram (often formulated as the oxalate salt) as the therapeutic component. This substance is entirely synthetic in origin, created through precise chemical processes, consistent with the majority of modern psychoanaleptics.

Escitalopram is primarily formulated for oral administration, most commonly available as a film-coated tablet or as an oral solution. Both forms offer flexibility for patient use, particularly the solution, which is sometimes preferred by patients who have difficulty swallowing tablets. The availability of these different formulations is a factor designed to aid adherence.


What is the General Purpose of This Type of Medicine?

The general purpose of a psychoanaleptic like Escitalopram is to promote the stabilization of the brain's emotional circuitry. The core benefit of this SSRI is to support overall mood regulation and to help gradually alleviate emotional distress that may stem from a chemical imbalance, such as an insufficiency of available serotonin. This type of medicine works to ensure that the natural chemical messenger remains active for a longer duration in the brain, fostering a calmer and more regulated state.

What side effects are possible with Zebinix (PSYCHOANALEPTICS)?

The official safety profile for this medicine is documented by government regulatory authorities, categorizing potential adverse reactions by frequency and affected physiological systems. The most common effects classified in official labeling as Very Common (ge 1/10) are Headache and Nausea.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (ge 1/100 to < 1/10) frequently involve the Gastrointestinal system (e.g., dry mouth, diarrhea, constipation), Nervous system (e.g., somnolence, dizziness, tremor), and Reproductive system (e.g., ejaculatory delay, decreased libido). Uncommon and rare effects are also documented.

Documented Serious Safety Concerns

Official labels detail serious but less frequent risks, including Serotonin Syndrome (a rare event, often associated with co-administration of other serotonergic drugs), Hyponatremia (low sodium levels), and the potential for Abnormal Bleeding. There is a documented risk of QT interval prolongation and Seizures/Convulsions.

Population-Specific Safety Statements

Regulatory warnings specify that older adults may be at an increased risk for Hyponatremia and bleeding events. In children, adolescents, and young adults (le 24 years), there is a documented increased risk of suicidal thoughts and behavior, particularly upon treatment initiation or dose adjustment. The medication is also not recommended for use in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations:

  • Neurological: Dizziness, Somnolence, Tremor, Confusion, Convulsions (Seizures), Coma.
  • Gastrointestinal: Nausea, Vomiting.
  • Autonomic/Other: Tachycardia (Rapid Heart Rate), Diaphoresis.

Physiological systems affected (as stated in label):

  • Central Nervous System (CNS), Cardiovascular System, Gastrointestinal System, Autonomic Nervous System.

Dose-related or exposure-related factors (if applicable):

  • Overdose risk is increased by co-ingestion with other serotonergic agents or medicines that prolong the QT interval.

Population-specific overdose notes (if applicable):

  • Patients with liver impairment may require closer ECG monitoring during overdose management due to altered metabolism.

Emergency-response statements (as written in official documents):

  • Seek immediate medical attention for any suspected overdose.
  • Immediately call emergency services if the individual has collapsed, experienced a seizure, or cannot be awakened.
  • Management requires symptomatic and supportive treatment and maintenance of the airway.

When immediate medical help is required (label-derived phrasing only):

  • Required when severe manifestations, such as Convulsions/Seizures, Coma, or signs of Cardiovascular Toxicity, are present.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Overdose may range from common signs to Severe or Life-Threatening events, including Cardiac Arrhythmia and Serotonin Syndrome.

Regulatory basis (EMA / FDA / etc.):

  • The information is based on post-marketing reports and clinical data summarized in the official FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Overdose-context constraints (as defined in official documents):

  • No specific antidote is known.
  • Continuous cardiac monitoring (ECG) is advised due to the risk of QT prolongation.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with documented signs including somnolence, vomiting, dizziness, and seizures.
  • Severe outcomes listed include QT prolongation, Ventricular Arrhythmia, and Serotonin Syndrome.
  • Seek immediate medical attention for all suspected overdose scenarios.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents explicitly define the overdose profile by listing expected neurological and cardiac manifestations that represent severe risk. The official labeling mandates that individuals seek immediate medical attention because no specific antidote exists and required management involves regulator-defined supportive measures, including continuous cardiac monitoring.

Therapeutic Uses of Zebinix (PSYCHOANALEPTICS)

What Escitalopram Treats: Main Uses and Benefits

The medication is commonly used to provide supportive relief for conditions marked by disruptive emotional and functional symptoms, focusing exclusively on easing the overall symptom load across key symptomatic domains.

The medication is indicated for use across major depressive and generalized anxiety disorders, where it contributes to managing symptomatic discomfort.


Symptomatic Relief and Indications

This medication is commonly used across conditions such as Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). It is applied in addressing symptom clusters that include profound sadness, excessive worry, loss of pleasure, chronic tension, and persistent restlessness.

It is used across domains where additional symptomatic support is needed, such as in managing panic attacks and severe social anxiety. By assisting with managing these functional components, the medication supports patients during difficult episodes and may assist with maintaining functional stability.

“It supports patients during episodes of heightened discomfort by easing distress and supporting general well-being.”


Quick Fact: Relief for Functional Strain
This medication may assist with managing symptoms that interfere with daily functioning, including persistent fatigue, challenges with concentration, and disturbances in sleep patterns.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Zebinix

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Zebinix (Eslicarbazepine Acetate).

Eligibility Status Applicable Population Constraint Description
Contraindicated Patients with known hypersensitivity to Eslicarbazepine acetate, Oxcarbazepine, or Carbamazepine [FDA/EMA]. Absolute prohibition against use.
Patients with second- or third-degree atrioventricular (AV) block [EMA]. Absolute prohibition against use.
Not Recommended Patients with severe hepatic impairment or severe renal impairment (CrCL < 30 mL/min) [FDA/EMA]. Use has not been studied in these groups.

Age-Related Eligibility

The medicine is approved for adults as monotherapy or adjunctive therapy. Pediatric eligibility varies by region and indication: the FDA approves adjunctive use for partial-onset seizures in patients 4 years of age and older, while the EMA approves adjunctive therapy for those above 6 years [FDA/EMA]. Safety and efficacy are not yet established in children aged 6 years and below (EMA standard).

Condition-Based Restrictions

Use requires special caution or adjustment for several populations. Patients with moderate to severe renal impairment (CrCL < 50 mL/min) must receive a dose adjustment [FDA]. Caution is also advised for geriatric patients, especially regarding the 1600 mg monotherapy dose, which is not recommended [EMA]. Furthermore, females of reproductive potential must use effective alternative contraception because Zebinix may reduce the effectiveness of hormonal contraceptives [FDA/EMA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zebinix (eslicarbazepine acetate) has a moderate potential for pharmacokinetic drug interactions, primarily by influencing the metabolism of other medicines in the liver. Its active metabolite, eslicarbazepine, acts as a moderate inducer of the CYP3A4 enzyme and a weak inducer of UDP-glucuronosyl transferase (UGT), while also being an inhibitor of the CYP2C19 enzyme.

Interacting Product Category Effect and Classification
Hormonal Contraceptives Decreased effectiveness due to enzyme induction (CYP3A4/UGT). Females of reproductive potential must use additional or alternative non-hormonal birth control.
Statins (e.g., Simvastatin) Decreased plasma concentration, potentially reducing efficacy. Requires monitoring and possible dose adjustment.
Enzyme-Inducing AEDs Concomitant use with drugs like Carbamazepine, Phenytoin, Phenobarbital, or Primidone reduces Zebinix's plasma concentrations. Higher doses of Zebinix may be necessary, and combined use increases the risk of certain adverse effects.

Combinations with Phenelzine or Ranolazine are not generally recommended. For medicines primarily metabolized by CYP2C19, their plasma levels may increase due to Zebinix’s inhibitory effect on this enzyme, necessitating dose adjustments.

Mechanism of Action

The mechanism of action for Zebinix is driven by its active metabolite, Eslicarbazepine, which limits membrane excitability within the central nervous system ( CNS) through the regulation of neuronal depolarization.

The primary action involves the molecule binding preferentially to the voltage-gated sodium channels ( VGSCs), specifically to the inactivated state. This stabilization effectively reduces the availability of the channels for subsequent activation, limiting the rapid flow of Na^+ ions essential for impulse generation. This molecular step initiates a cascade that results in a limitation of sustained repetitive neuronal firing.

This drug exerts a use-dependent blockade, meaning its effect is strongest on neurons engaged in sustained repetitive firing, which is characteristic of hyperactivity, while having minimal interference with normal, low-frequency physiological signaling. The resulting physiological effect is a stabilization of the neuronal membrane potential and a restriction of the rapid and excessive transfer of electrical discharges across CNS circuits. This focused modulation establishes a physiologically more constrained state within targeted neural pathways.

Dosage and Administration Information

Standardized Administration Guidelines for Zebinix (Eslicarbazepine Acetate)

The following instructions detail the standardized procedure for using Zebinix.

Route and Frequency

Zebinix is strictly for oral use and must be taken once daily (OD).

General Dosing Protocol (Titration)

Administration begins with a low initial dose (e.g., 400 mg once daily for adults). The dose is then gradually increased—typically after one to two weeks—until the patient reaches the prescribed maintenance dose (e.g., 800 mg to 1,200 mg once daily for adults). This gradual increase (titration) is a mandatory procedural step.

Administration Details

  • Timing: The medicine may be taken with or without food.
  • Form Preparation: Tablets can be swallowed whole with water. For patients unable to swallow whole tablets, they may be crushed and mixed with a small amount of water or soft food (such as applesauce) and must be taken immediately.
  • Missed Dose: If a dose is missed, the patient should not take a double dose; the next dose should be taken at the regularly scheduled time the following day.

Population-Specific Dosing Rules

Population Procedural Constraint
Pediatric (Age ge 6 years) Dosing for patients under 60 kg is calculated based on body weight (mg/kg/day).
Renal Impairment Patients with moderate impairment (Creatinine Clearance CLCR 30-60 ml/min) require a reduced starting dose and maintenance dose (e.g., 400 mg once daily). Use is not recommended for severe impairment.
Discontinuation Treatment must be reduced gradually to avoid the risk of increased seizure frequency.

These administration guidelines define the proper initiation, maintenance, and cessation of treatment based on the patient's individual physiological status.

Recent Clinical Evidence

Research evidence / Overview of Studies for Escitalopram

This overview summarizes the structure and reported findings of the clinical research for escitalopram, drawing on studies described in authoritative regulatory and scientific literature. The evidence is derived primarily from structured trials designed to assess patterns of short-term change and results measured over longer follow-up periods.


Evidence for use in Major Depressive Disorder (MDD)

Research evidence for Major Depressive Disorder (MDD) includes short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring patterns of symptom change over defined time intervals, typically over six to eight weeks. Researchers monitored measurements related to symptom intensity using standardized tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS). The research describes patterns observed in measured symptom scores and the proportion of participants whose scores met pre-defined criteria for response or remission during the study period. Research has also explored the application of escitalopram in patients presenting with additional anxiety symptoms.


Evidence for use in Generalized Anxiety Disorder (GAD)

Research evidence for Generalized Anxiety Disorder (GAD) includes short-term (8-week) placebo-controlled RCTs in adult populations. The research explored results measured related to conditions characterized by functional limitations. The main measurements were related to physical discomfort and patient-reported observations describing perceived discomfort, such as the Hamilton Anxiety Rating Scale (HAMA). Research highlights changes measured during the study period for GAD, with trials reporting the evolution of anxiety symptom scores and the proportion of participants achieving a specified level of improvement.


Long-Term Follow-up and Limitations

Research has included maintenance trials for MDD, which followed patients who had achieved a desired symptom status to examine the duration of the monitored status and assess patterns of longer-term symptom management, with observation periods extending up to a year. However, the systematic study of long-term results measured for GAD symptoms is not fully characterized in all regulatory records compared to the data for MDD. Furthermore, the results apply only to the populations studied; evidence is limited for those with complex clinical presentations, and findings were mixed in some studies involving adolescents.

Frequently Asked Questions (FAQ)

Common questions about Zebinix (PSYCHOANALEPTICS) (FAQ)

Q: What is Zebinix used for besides what the doctor said?

Official information indicates that Zebinix is used to treat partial-onset seizures, which are seizures that start in one area of the brain. It is approved for use in adults as a sole treatment (monotherapy) or as an add-on treatment (adjunctive therapy). It can also be used as adjunctive therapy in children.

Q: Is Zebinix a new version of an older medicine?

Zebinix (Eslicarbazepine Acetate) is a medicine chemically related to two other older antiepileptic drugs (AEDs): carbamazepine and oxcarbazepine. It is considered a type of prodrug, meaning it is quickly converted in the body into the active compound, eslicarbazepine, which then works to manage seizures.

Q: Why is Zebinix classified as a PSYCHOANALEPTIC?

While the core therapeutic role of Zebinix is as an antiepileptic drug, the classification psychoanaleptic is a broad pharmacological term sometimes used to describe medications that may modulate the function of the Central Nervous System (CNS). This classification reflects the drug's known site of action in the brain.

Q: How quickly should Zebinix start working?

Official product information suggests that the active substance, eslicarbazepine, typically reaches a stable concentration in the bloodstream (steady-state) after about four to five days of once-daily dosing. The overall effect is typically evaluated by a healthcare professional as the dose is gradually adjusted during the initial weeks.

Q: Does Zebinix cause weight gain or weight loss?

According to regulatory documents, an increase in weight is a documented Common side effect associated with the use of Zebinix.

Q: Do you have to take Zebinix at the exact same time every day?

Zebinix is designed as a once-daily medication. Its long half-life supports once-daily dosing. Maintaining a consistent once-daily schedule helps support stable blood levels.

Q: Can Zebinix affect mood or cause mood changes?

Official warnings in the drug's labeling discuss the documented potential for an increased risk of suicidal thoughts or behavior. This risk is specified particularly for children, adolescents, and young adults, especially when initiating treatment or adjusting the dose.

Q: Does alcohol interact with Zebinix?

Official safety information indicates that consuming alcohol while using Zebinix may intensify side effects related to the brain, such as dizziness, drowsiness, confusion, or difficulty concentrating. This occurs because both substances can depress Central Nervous System (CNS) function.

Q: Is Zebinix addictive or habit-forming?

Zebinix (Eslicarbazepine Acetate) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) and is not generally considered to be a habit-forming medicine.

Q: How is Zebinix different from other similar epilepsy medicines?

It differs from its relative, carbamazepine, in that it is metabolized into the active substance eslicarbazepine without producing the toxic metabolite known as carbamazepine-10,11-epoxide. This chemical difference results in a pharmacological profile that is distinct from its related compounds.

Q: Can Zebinix cause skin issues or rashes?

Official labeling contains warnings regarding the rare but documented potential for serious and potentially life-threatening skin reactions, including Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The labeling indicates that monitoring for signs of rash or fever may be necessary.

Q: Does Zebinix interact with common pain relievers like ibuprofen?

Zebinix can influence the liver enzymes, specifically CYP3A4 and CYP2C19, which are responsible for breaking down many medications. While common pain relievers are not always individually listed in official documents, caution is advised when combining medications that affect these enzyme pathways.

Q: Do you need special blood tests while taking Zebinix?

The drug carries a risk of causing hyponatremia (low sodium levels in the blood), which is a serious side effect. Because of this, monitoring of blood sodium levels is often necessary when treatment is initiated or doses are adjusted.

Q: Is Zebinix available as a generic medicine?

Yes, the active ingredient eslicarbazepine acetate is available in generic form.

Q: How long can someone safely stay on Zebinix?

Zebinix is approved for the chronic treatment of partial-onset seizures, and clinical trials have included long-term extension studies lasting a year or more. The duration of therapy is a decision determined by the treating healthcare provider based on individual patient need.

Q: Does Zebinix have a high risk of interaction with herbal supplements?

Zebinix can affect liver enzymes like CYP3A4, which are also targeted by some herbal supplements. Herbal products that affect these enzyme systems, such as St. John's Wort, could potentially lead to interactions.

Q: Does Zebinix work the same way for everyone?

The official labeling indicates that patient response can vary. Dosing must be individualized based on the patient's tolerability, clinical response, and factors like kidney function, suggesting that the drug's effects can differ significantly.

Q: Why do doctors switch patients to Zebinix from other medicines?

Zebinix is approved to be used as the sole therapy (monotherapy) for partial-onset seizures, which allows for switching. It provides an alternative with a distinctive mechanism of action and tolerability profile compared to chemically related antiepileptic drugs.

Q: Does Zebinix interact with acid reflux medications?

Zebinix is an inhibitor of the CYP2C19 enzyme in the liver. Some common acid reflux medications, such as omeprazole, are metabolized by this enzyme. This suggests a potential interaction where the level of the acid reflux medication may increase, and professional monitoring may be necessary.

Q: What kind of research has been done on Zebinix?

The efficacy of Zebinix was established through several large-scale, randomized, double-blinded, placebo-controlled clinical trials. These studies compared the drug's performance against a placebo in adults with partial-onset seizures.

Q: Can Zebinix be taken during pregnancy?

Official labeling, based largely on animal studies, indicates that the drug may cause fetal harm. Due to limited data in humans, official documents describe the need to communicate potential risks to patients, and enrollment in a pregnancy exposure registry is noted as a resource.

Q: Is there official information about using Zebinix while breastfeeding?

The drug is known to pass into human milk. Regulatory authorities note that a risk to the nursing infant cannot be excluded. Official information discusses the importance of monitoring the infant for signs like drowsiness and weight changes, and some official guidance notes that discontinuation of breastfeeding may be considered.

Q: What are the most common reasons people stop taking Zebinix?

Data from clinical trials show that the most common reasons for treatment discontinuation were side effects such as dizziness, nausea, vomiting, somnolence, and fatigue. These adverse events were reported to occur more frequently at higher doses.

Q: Is it possible for Zebinix to make symptoms worse initially?

Official warnings state that stopping the medicine abruptly carries the risk of increased seizure frequency or a worsening condition, known as status epilepticus. Patients are also closely monitored for adverse reactions during the initial gradual increase (titration) of the dose.

Q: What is the half-life of Zebinix as described in official documents?

The half-life—the time it takes for half of the drug's active metabolite to be cleared from the bloodstream—is reported in official documents to be approximately 13 to 20 hours.

Q: Is the efficacy of Zebinix supported by long-term clinical trials?

Yes. Following the initial short-term efficacy studies, the maintenance of the therapeutic effect and long-term safety were assessed in follow-up open-label extension studies that lasted for approximately one year.

Q: Why are the dosage forms of Zebinix specific shapes or colors?

The different dosage strengths of the tablets are manufactured with specific colors and engravings (such as 'ESL' and the strength number). This is a required measure intended to allow for positive identification of the tablet strength and to prevent accidental administration errors.

Q: Can Zebinix affect driving ability or reaction time?

Yes. Official product information includes warnings that the drug may have a minor to moderate influence on the ability to drive and use machines. This is due to common adverse effects such as dizziness and somnolence (drowsiness).

Q: Are there restrictions on working certain jobs while taking Zebinix?

Regulatory labeling advises patients to use caution before operating complex machinery, driving a motor vehicle, or performing other potentially hazardous activities. This is specifically due to the risk of side effects like dizziness and somnolence.

Q: Is Zebinix linked to any vitamin deficiencies?

As a member of the Antiepileptic Drug (AED) class, this medicine may contribute to folic acid deficiency. This is a recognized consideration, with some guidance discussing the possibility of supplementation.

How should Zebinix (PSYCHOANALEPTICS) be stored and disposed of?

How to Store and Dispose of Zebinix (PSYCHOANALEPTICS)?

Official regulatory documents define specific requirements for storing and discarding Zebinix (eslicarbazepine acetate) to maintain its stability and ensure safety.


Official Storage Requirements

Zebinix tablets generally require room temperature storage, with no special conditions mandated by European labels. However, all forms must be protected from excess heat and excess moisture and kept in the original container with the lid tightly closed.

Product Form Stability Constraint
Oral Suspension Discard if unused after 2 months of opening the bottle.
All Forms Must be kept out of the sight and reach of children.

Disposal Constraints

Unused or expired Zebinix must not be thrown away with household waste or poured down the wastewater. Users are instructed to consult a pharmacist to learn the proper procedure for discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zebinix (PSYCHOANALEPTICS) found in:

A-Z Index: